Metoprolol succinate SR plus hydrochlorothiazide (Beloc-Zok® Comp) in patients with essential hypertension in general practice: A prospective, observational trial in 14 964 patients

Clinical Drug Investigation

Volumn 22, Issue 11, 2002, Pages 719-729

  Hildemann, Steven K ^a   Fischer, H ^b   Pittrow, D ^c   Bohlscheid, V ^d  

^a Pharmacia GmbH   (Germany)

^b Krankenhaus Vincentinum   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Dietrich Bonhoeffer Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BELOC ZOK COMP; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS METOPROLOL SUCCINATE; METOPROLOL TARTRATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; GENERAL PRACTICE; GERMANY; HEART DISEASE; HEART RATE; HUMAN; HYPERTENSIVE CRISIS; IMPOTENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; UTERUS CARCINOMA; VERTIGO; VOMITING;

EID: 0036436746     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222110-00001     Document Type: Article

References (29)

1. Joint National Committee on Prevention, Detection, Evaluation, et al. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-42
2. WHO/ISH Hypertension Guidelines Subcommittee. 1999 WHO-ISH guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
3. Coca A. Actual blood pressure control: Are we doing things right? J Hypertens 1998; 16 (1): S45-51
4. Mancia G, Sega R, Milesi C, et al. Blood-pressure control in the hypertensive population. Lancet 1997; 349 (9050): 454-7
5. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: Results from the health survey for England 1994. J Hypertens 1998; 16 (6): 747-52
6. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21
7. Philipp T, Anlauf M, Distler A, et al. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study. HANE Trial Research Group. BMJ 1997; 315 (7101): 154-9
8. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertensive Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62
9. Stanton T, Reid JL. Fixed dose combination therapy in the treatment of hypertension. J Hum Hypertens 2002; 16: 75-8
10. Benfield P, Clissold SP, Brogden RN. Metoprolol: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 1986; 31 (5): 376-429
11. Plosker GL, Clissold SP. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs 1992; 43 (3): 382-414
12. Leikersfeldt G, Rasmussen SL, Atmer B, et al. Efficacy and tolerability of a fixed combination of metoprolol CR/ZOK 100mg and hydrochlorothaizide (HCT) 12.5mg in comparison with the fixed combination of metoprolol and HCT. J Clin Pharmacol 1990; 30 Suppl.: S78-81
13. SAS. Release 6.0. Cary (NC): SAS Institute Inc., 1999
14. Committee of Safety of Medicines. Adverse Reactions Working Party: Second Report. London: HMSO, 1986
15. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339 (27): 1957-63
16. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26 (1): 60-9
17. Neutel JM, Smith DHG, Weber MA. Low-dose combination therapy: An important first-line treatment in the management of hypertension. Am J Hypertens 2001; 14: 286-92
18. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12 (8): 533-7
19. McCombs JS, Nichol M, Newman C, et al. The cost of interrupting antihypertensive therapy in the Medicaid population. Med Care 1994; 32: 214-6
20. Sica DA. Fixed dose combination antihypertensive drugs: Do they have a role in rational therapy? Drugs 1994; 48: 16-24
21. Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61 (7): 943-54
22. Ambrosioni E. Pharmacoeconomics of hypertension management: The place of combination therapy. Pharmacoeconomics 2001; 19 (4): 337-47
23. Pittrow DB, Antlsperger A, Welzel D, et al. Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. Cardiovasc Drugs Ther 1997; 11 (5): 619-27
24. Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: Amlodipine 5mg/benazepril 20mg compared with amlodipine 5mg, benazepril 20mg, and placebo. Clin Ther 1996; 18 (6): 1213-24
25. Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. Am J Hypertens 1998; 11 (3): 322-7
26. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356 (9246): 1955-64
27. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359 (9311): 995-1003
28. Schulte KL, Fischer M, Lenz T, et al. Efficacy and safety of candesartan cilexitil monotherapy or in combination with other antihypertensive drugs. Clin Drug Invest 1999; 18 (6): 453-60
29. Olvera S, Alcocer L, Novoa G. Usefulness of low-dose, once-daily quinapril as monotherapy for patients with hypertension. Clin Ther 1996; 18 (5): 864-73